Psoriasishttps://en.wikipedia.org/wiki/Psoriasis
☆ A cikin sakamakon Stiftung Warentest na 2022 daga Jamus, gamsuwar mabukaci tare da ModelDerm ya ɗan yi ƙasa kaɗan fiye da biyan shawarwarin telemedicine. relevance score : -100.0%
References Psoriasis 28846344 NIH
Phototherapy 33085287 NIH
Tumor Necrosis Factor Inhibitors 29494032 NIH
Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C), and golimumab (G), are biologic agents which are FDA-approved to treat ankylosing spondylitis (E, I, A, C, and G), Crohn disease (I, A and C), hidradenitis suppurativa (A), juvenile idiopathic arthritis (A), plaque psoriasis (E, I and A), polyarticular juvenile idiopathic arthritis (E), psoriatic arthritis (E, I, A, C, and G), rheumatoid arthritis (E, I, A, C, and G), ulcerative colitis (I, A and G), and uveitis (A).
Jiyya daban-daban na iya taimakawa wajen sarrafa alamun. Waɗannan magungunan sun haɗa da kirim ɗin steroid, kirim na bitamin D3, hasken ultraviolet, da magungunan rigakafi, irin su methotrexate. Kimanin kashi 75% na shigar fata yana inganta tare da creams kadai. Ana haɓaka nau'ikan nau'ikan ƙwayoyin cuta na rigakafi don maganin psoriasis.
Psoriasis cuta ce ta gama gari kuma cutar tana shafar kashi 2-4% na yawan jama'a. Maza da mata abin ya shafa daidai gwargwado. Cutar na iya farawa a kowane zamani, amma yawanci tana farawa tun lokacin girma. Psoriatic amosanin gabbai yana shafar kusan kashi 30% na mutanen da ke da psoriasis.
○ Jiyya - Magungunan OTC
Hasken rana zai iya taimakawa psoriasis saboda bayyanar rana yana haifar da canje-canje na rigakafi a cikin marasa lafiya tare da psoriasis. Maganin shafawa mai laushi na hydrocortisone na iya taimakawa wajen magance wasu ƙananan raunuka na psoriasis.
#OTC steroid ointment
○ Magani
Psoriasis cuta ce ta yau da kullun kuma ana nazarin magungunan magani da yawa. Ilimin halittu sune mafi inganci amma tsada sosai.
#High potency steroid ointment
#Calcipotriol cream
#Phototherapy
#Biologics (e.g. infliximab, adalimumab, secukinumab, ustekinumab)